Skip to content

Abstract B001: Cancer-associated fibroblast p38α MAPK signaling coordinates collagen architecture and immune suppression to drive chemoresistance in pancreatic cancer

Sep 2026 · Cancer Research · 0 citations

TL;DR

This work identified p38α MAPK (p38α; MAPK14) as a key regulator of inflammatory CAF activation and collagen remodeling and implicates it as a central mediator of stromal remodeling and therapeutic resistance in pancreatic cancer.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains highly refractory to chemoimmunotherapy due in large part to its dense, immunosuppressive stroma. Cancer-associated fibroblasts (CAFs), the dominant stromal cell population, promote tumor progression through inflammatory signaling, aligned collagen-rich extracellular matrix (ECM), and immune exclusion. Broad-based CAF depletion strategies have failed clinically, underscoring the need to selectively target pro-tumorigenic CAF functions. We identified p38α MAPK (p38α; MAPK14) as a key regulator of inflammatory CAF activation and collagen remodeling. p38α signaling is further induced in stroma-rich patient tumors and following treatment with chemotherapy, implicating it as a central mediator of stromal remodeling and therapeutic resistance. Human and murine CAFs underwent pharmacologic inhibition or CRISPR-Cas9-mediated deletion of MAPK14. Inflammatory and matrix programs were assessed by RNA sequencing, cytokine profiling, and collagen fiber angle-orientation analysis. Tumor-cell proliferation, invasion, mechanosensing, and focal-adhesion formation were evaluated in co-culture and on decellularized CAF-derived matrices. An inducible fibroblast-specific Col1a2 Cre/ERT2;Mapk14 flox/flox (CAF-p38 KO) mouse model was generated and used with orthotopic PDAC tumors to evaluate tumor burden, stromal architecture, immune composition, and response to gemcitabine/paclitaxel chemotherapy. MAPK14-dependent signaling was enriched in fibroblast-rich human PDAC and was further activated in CAFs by chemotherapy. Genetic deletion or pharmacologic inhibition of p38α in CAFs concordantly suppressed IL6 secretion and myeloid chemoattraction, reduced extracellular-matrix programs, and decreased collagen alignment. Tumor cells exposed to p38α-deficient CAFs or their decellularized matrices exhibited impaired proliferation and invasion, reduced mechanosensing, and fewer paxillin-positive focal adhesions. In vivo, fibroblast-specific Mapk14 deletion reduced orthotopic tumor burden, attenuated inflammatory CAF programs, and decreased collagen deposition. Flow cytometry demonstrated fewer total, monocytic, and polymorphonuclear myeloid-derived suppressor cells, increased cytotoxic T cell infiltration, and reduced regulatory T cells, consistent with stromal reprogramming towards a tumor-restraining phenotype. Strikingly, treatment with chemotherapy increased CAF p38α activation, inflammatory CAF abundance, and intratumoral fibrosis. CAF-p38 KO mice treated with chemotherapy demonstrated significantly improved survival compared to control mice. CAF-intrinsic p38α MAPK coordinates inflammatory signaling, collagen architecture, and tumor mechanotransduction to establish an immune-suppressive, treatment-resistant PDAC microenvironment. Selective p38α disruption reprograms rather than depletes fibroblasts and enhances chemotherapy efficacy, identifying a rational stromal therapeutic strategy. Camille M. Acevedo, Sayan Chakraborty, Samara Singh, Edmond W. Box, Andrew M. Adams, Karthik Rajkumar, Haleh Amirian, Jashodeep Datta, Nagaraj Nagathihalli, Austin Dosch, Nipun B. Merchant. Cancer-associated fibroblast p38α MAPK signaling coordinates collagen architecture and immune suppression to drive chemoresistance in pancreatic cancer [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr B001.

View source

Similar papers

Sep 2026

Abstract A006: A p38α MAPK-TCF21 axis regulates pancreatic stellate cell activation and stromal reprogramming in pancreatic cancer

Pancreatic stellate cells (PSCs) are a principal source of cancer-associated fibroblasts (CAF) in pancreatic ductal adenocarcinoma (PDAC), yet the mechanisms that convert tumor-derived inflammatory cues into a persistent, CAF-like state remain poorly defined. We previously identified tumor cell-intrinsic p38α MAP...

Sayan Chakraborty, Camille Acevedo, Samara P. Singh et al. · 0 citations
Sep 2026

Abstract B006: Actin Cytoskeleton Dynamics in Tumor Cells Orchestrate Stromal Desmoplasia and Immune Evasion in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is defined by a dense, immunosuppressive tumor microenvironment (TME) enriched with extracellular matrix components, cancer-associated fibroblasts (CAFs), and diverse immune populations. ChIP-seq analysis of resected human PDAC identified MICAL2 as a super-enhancer–associat...

Bharti Garg, E. Mose, Briana Nyugen et al. · 0 citations
Open access Sep 2026

Targeting CTGF+ cancer-associated fibroblasts disrupts tumor-stroma crosstalk in pancreatic ductal adenocarcinoma.

Targeting CTGF+ CAFs with QX03-46 significantly disrupted the CTGF/TGF-β1 signaling axis and suppressed CAF functions, resulting in decreased extracellular matrix deposition and oncogenic cytokine secretion and position QX03-46 as a promising therapeutic candidate for targeting the fibrotic TME.

Yi-Wen Shen, Qing-Yan Sun, Yun-Zhe Wang et al. · 0 citations
Open access Sep 2026

Cancer-associated fibroblasts drive immune resistance in MSS colorectal cancer via the FAIM2-CES1-ER stress pathway

Findings reveal a potential FAIM2-CES1-ER stress axis in CAFs associated with ECM remodeling and immune contexture in MSS CRC, providing a rationale for future studies exploring its therapeutic potential in immunotherapy.

Ren Tang, Hong-Tao Wan, Meng-Lan Zhong et al. · 0 citations
Sep 2026

Abstract A019: Tumor Nutrient Stress Regulates Cancer-associated Fibroblast Heterogeneity

Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer type with a 5-year survival rate of only 13%. PDAC is unique in that up to 90% of the tumor bulk is comprised of a dense desmoplastic stroma. Enriched within PDAC’s extensive stroma are cancer-associated fibroblasts (CAFs). CAFs orchestrate tumor progression...

Marta R. Storl-Desmond, Nicole Liu, K. Forti et al. · 0 citations
Sep 2026

Abstract B101: Stroma-tumor crosstalk converges with oncogenic KRAS signaling to drive an NFκB-mediated immune evasion program

An immunosuppressive tumor microenvironment (TME) is a hallmark of pancreatic ductal adenocarcinoma (PDAC), rendering most tumors resistant to immunotherapy approaches. Importantly, “tumor-to-stroma” crosstalk downstream of oncogenic KRAS has emerged as a major driver of immune evasion in PDAC, however the role of re...

Yuwenbin Li, Morgan L. Truitt, Dan Cao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.